iosBio

iosBio is a biotechnology company developing thermostable oral vaccines using adenoviral vector delivery.

Its platform protects vaccine vectors to survive stomach transit and release in the lower small intestine, inducing mucosal and systemic immunity without cold chain requirements or needle administration.

The lead programme targets Epstein-Barr virus, with preclinical data demonstrating class-leading antibody responses; a Phase 1 trial is in preparation.

The broader pipeline spans influenza, Zika and coronavirus, supported by AI-assisted antigen design.